HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

April 27, 2023 updated by: Thunder Bay Regional Health Research Institute

Hyperpolarized Xenon-129 Functional Magnetic Resonance Imaging of Healthy Volunteers and Participants With Alzheimer's Disease

This study involves imaging participants' brains using MRI. The goal is to develop a high-resolution, high-sensitivity imaging tool, hyperpolarized xenon functional brain magnetic resonance imaging, which can provide more sensitive measurement of brain function, facilitating the development of drugs for more successful treatment of Alzheimer's disease.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The described study is a pilot study in which the investigators aim to develop an enhanced sensitivity tool for assessment of neural function. Participation involves at least two study visits no longer than three hours in length each. During visit 1, informed consent and screening for eligibility will take place. During visit 2, fMRI scanning will take place in which participants will complete simple tasks. Two types of MRI scans will be performed: traditional proton fMRI and hyperpolarized xenon-129 fMRI (HP 129Xe fMRI) scans. The trade name for xenon-129 hyperpolarized with a Xemed LLC polarizer is NeuroXene.

Participants will be placed in the 3T MRI at the Thunder Bay Regional Research Institute with a Clinical MR Solutions (CMRS) Dual Brain Coil that fits over their head like a helmet. Several inhalation procedures will be performed by participants when breathing NeuroXene from a tube in the scanner. Preparation and administration of NeuroXene and the CMRS Dual Brain Coil will be carried out according to the SOP's developed by the TBRRI and Xemed LLC.

MRI scanning will be performed with a MR Tech and Registered Respiratory Therapist present. Dispensing of 129Xe will be monitored using a gas dispensing form and a drug accountability log. This study will have a monitor assigned to it from the TBRRI that is not involved in this clinical trial. This is to ensure participant safety and adherence to the protocol.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mitchell Albert, Ph.D.
  • Phone Number: 807-684-7270
  • Email: albertmi@tbh.net

Study Contact Backup

  • Name: Jennifer Plata, HBSc
  • Phone Number: 807-684-7270
  • Email: plataj@tbh.net

Study Locations

  • Canada
    • Ontario
      • Thunder Bay, Ontario, Canada, P7B 6V4
        • Recruiting
        • Thunder Bay Regional Health Sciences Centre
        • Contact:
        • Principal Investigator:
          • Mitchell S Albert, PhD
        • Sub-Investigator:
          • Karl Granberg, MD
        • Contact:
          • Francis Hane, PhD
          • Phone Number: 807-684-6958
          • Email: hanef@tbh.net
        • Sub-Investigator:
          • Jane Lawrence-Dewar, PhD
        • Sub-Investigator:
          • Francis Hane, PhD
        • Sub-Investigator:
          • Ayman Hassan, MD
        • Sub-Investigator:
          • Alla Reznik, PhD
        • Sub-Investigator:
          • Anton Kolobov, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

A participant is eligible for inclusion in the study if the individual meets all of the following criteria:

  1. Self-reported proficiency in English language.
  2. Equal to or more than 8 years of education.
  3. Normal or corrected to normal vision.
  4. Able to provide informed consent.
  5. Able to hold their breath for 20 seconds.

Normal cognition for healthy participant group inclusion criteria:

  1. Preserved independence in functional abilities.
  2. MoCA score no less than 26.
  3. Males and non-lactating females of 18 to 85 years of age.

Alzheimer's disease group inclusion criteria:

  1. Participants meet National Institute on Aging-Alzheimer's Association for probable or possible Alzheimer's Disease dementia.
  2. MoCA score no less than 16.
  3. Males and non-lactating females of 60 to 85 years of age.
  4. Have a family member, close friend, or LAR that can be present for the informed consent process and study visits.

Exclusion Criteria:

A participant is ineligible for the study if the individual meets any of the following criteria:

  1. Serious underlying medical condition, other, then the condition being investigated, which may affect cognitive function of the participant (in the opinion of the investigator): substance abuse, psychotic or depressive disorder, advanced or poorly controlled cardiac, pulmonary, hepatic, renal, neurological disorders in which the patient has significant speech, visual, motor or cognitive deficit, seizure disorders, endocrine or infectious disease or active malignancy.
  2. MRI incompatibility as determined by MR Technologist during MRI screening.
  3. Self-identifies as claustrophobic.
  4. Female exclusion only: Are or may be pregnant; Planning on becoming pregnant.
  5. Is a student currently enrolled in a course at Lakehead University where the Principal Investigator (PI) is the instructor.
  6. Is a student currently enrolled in a degree program at Lakehead University where the PI is their direct thesis supervisor.
  7. Is currently an employee of the PI at the Thunder Bay Regional Research Institute (TBRRI) and/or Lakehead University.

Normal cognition group exclusion criteria:

1. History of diagnosed neurological disease or injury.

Alzheimer's disease group exclusion criteria:

  1. Existing diagnosis of dementia of etiology other than Alzheimer's disease.
  2. Acute Delirium on the day of scanning (CAM tool assessment)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Healthy Volunteers
Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
Other: Traditional Proton fMRI
Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
Other: Hyperpolarized Xenon-129 fMRI
HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
Other Names:
  • HP 129Xe fMRI
Drug: Hyperpolarized Xenon-129
Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Other Names:
  • NeuroXene
Device: 1H-129Xe Dual-Tuned Quadrature Head Coil
A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
Other: Alzheimer's Disease Participants
Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
Other: Traditional Proton fMRI
Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
Other: Hyperpolarized Xenon-129 fMRI
HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
Other Names:
  • HP 129Xe fMRI
Drug: Hyperpolarized Xenon-129
Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Other Names:
  • NeuroXene
Device: 1H-129Xe Dual-Tuned Quadrature Head Coil
A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Signal-to-Noise Ratio (SNR)
Time Frame: Three years
All scans will be optimized for the highest SNR possible; No aggregation of data
Three years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
P-Value
Time Frame: Three years
To be calculated from a students paired t-test for signal change between healthy participant scans and participants with Alzheimer disease
Three years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thunder Bay Regional Health Research Institute

Collaborators

Lakehead University
Thunder Bay Regional Health Sciences Centre

Investigators

  • Principal Investigator: Mitchell Albert, Ph.D., Thunder Bay Regional Health Research Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 27, 2016

Primary Completion (Anticipated)

January 28, 2026

Study Completion (Anticipated)

January 28, 2026

Study Registration Dates

First Submitted

December 3, 2015

First Submitted That Met QC Criteria

December 18, 2015

First Posted (Estimate)

December 23, 2015

Study Record Updates

Last Update Posted (Actual)

May 1, 2023

Last Update Submitted That Met QC Criteria

April 27, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RP-307-08312015

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Traditional Proton fMRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe